Vertex Pharmaceuticals
VRTX · Nasdaq · Health Care
☆ Follow
Shareholder advocacy aimed at Vertex Pharmaceuticals
Nothing recorded yet. That means no campaign in our database names this company, not that none exists.
What shareholders voted on
From Vertex Pharmaceuticals’s own filings with the SEC. Support is the share of votes cast for and against, so abstentions and broker non-votes are not counted in it.
2026
2025
| Item | Kind | Asked for by | Support | Outcome |
|---|---|---|---|---|
| Based upon the following votes, the shareholders approved, on an advisory basis, the 2024 compensation program for the Company's named executive officers | Company proposal | 92.5% | Passed | |
| Based upon the following votes, the shareholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2025 | Auditor | 97.1% | Passed | |
| Election of Reshma Kewalramani | Director | 99.8% | Passed | |
| Election of Jennifer Schneider | Director | 99.6% | Passed | |
| Election of Diana McKenzie | Director | 99.3% | Passed | |
| Election of Suketu Upadhyay | Director | 99.2% | Passed | |
| Election of Sangeeta Bhatia | Director | 99.1% | Passed | |
| Election of Nancy Thornberry | Director | 98.7% | Passed | |
| Election of Michel Lagarde | Director | 98.7% | Passed | |
| Election of Alan Garber | Director | 98.3% | Passed | |
| Election of Jeffrey Leiden | Director | 97.6% | Passed | |
| Election of Lloyd Carney | Director | 96.1% | Passed | |
| Election of Bruce Sachs | Director | 93.6% | Passed |
2024
2023
| Item | Kind | Asked for by | Support | Outcome |
|---|---|---|---|---|
| Based upon the following votes, the shareholders approved, on an advisory basis, the 2022 compensation program for the Company's named executive officers | Company proposal | 89.5% | Passed | |
| Based upon the following votes, the shareholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2023 | Auditor | 96.7% | Passed | |
| Election of Suketu Upadhyay | Director | 99.3% | Passed | |
| Election of Reshma Kewalramani | Director | 99.3% | Passed | |
| Election of Alan Garber | Director | 99% | Passed | |
| Election of Diana McKenzie | Director | 98.9% | Passed | |
| Election of Sangeeta Bhatia | Director | 98.9% | Passed | |
| Election of Jeffrey Leiden | Director | 96.5% | Passed | |
| Election of Terrence Kearney | Director | 94.6% | Passed | |
| Election of Lloyd Carney | Director | 93.1% | Passed | |
| Election of Bruce Sachs | Director | 90.8% | Passed |
2022
| Item | Kind | Asked for by | Support | Outcome |
|---|---|---|---|---|
| Suketu “Suky” Upadhyay | Company proposal | 99.7% | Passed | |
| Based upon the following votes, the shareholders approved, on an advisory basis, the 2021 compensation program for the Company’s named executive officers | Company proposal | 92.6% | Passed | |
| Based upon the following votes, the shareholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2022 | Auditor | 77.4% | Passed | |
| Election of Reshma Kewalramani | Director | 99.5% | Passed | |
| Election of Diana McKenzie | Director | 99.3% | Passed | |
| Election of Sangeeta Bhatia | Director | 99.3% | Passed | |
| Election of Alan Garber | Director | 98% | Passed | |
| Election of Margaret McGlynn | Director | 97.8% | Passed | |
| Election of Yuchun Lee | Director | 97.8% | Passed | |
| Election of Jeffrey Leiden | Director | 96.8% | Passed | |
| Election of Bruce Sachs | Director | 94.6% | Passed | |
| Election of Terrence Kearney | Director | 89.6% | Passed | |
| Election of Lloyd Carney | Director | 86.7% | Passed |
2021
| Item | Kind | Asked for by | Support | Outcome |
|---|---|---|---|---|
| Based upon the following votes, the shareholders approved, on an advisory basis, the 2020 compensation program for the Company's named executive officers | Company proposal | 91.4% | Passed | |
| Based upon the following votes, the shareholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2021 | Auditor | 87.6% | Passed | |
| Election of Diana McKenzie | Director | 99.9% | Passed | |
| Election of Reshma Kewalramani | Director | 99.7% | Passed | |
| Election of Sangeeta Bhatia | Director | 99.7% | Passed | |
| Election of Margaret McGlynn | Director | 99.5% | Passed | |
| Election of Yuchun Lee | Director | 98.2% | Passed | |
| Election of Alan Garber | Director | 98.2% | Passed | |
| Election of Jeffrey Leiden | Director | 97.6% | Passed | |
| Election of Terrence Kearney | Director | 96.9% | Passed | |
| Election of Bruce Sachs | Director | 95.1% | Passed | |
| Election of Lloyd Carney | Director | 78.1% | Passed |
2020
2019
2018
Proxy statements and vote results
Straight from Vertex Pharmaceuticals’s own SEC filings. The proxy statement lists what shareholders were asked to vote on; the 8-K certifies how the vote went.
| Year | Filing | Filed |
|---|---|---|
| 2026 | Vote results | 2026-05-13 |
| 2026 | Proxy statement | 2026-04-02 |
| 2025 | Vote results | 2025-05-14 |
| 2025 | Proxy statement | 2025-04-03 |
| 2024 | Vote results | 2024-05-15 |
| 2024 | Proxy statement | 2024-04-04 |
| 2023 | Vote results | 2023-05-18 |
| 2023 | Proxy statement | 2023-04-06 |
| 2022 | Vote results | 2022-05-18 |
| 2022 | Proxy statement | 2022-04-07 |
| 2021 | Vote results | 2021-05-19 |
| 2021 | Proxy statement | 2021-04-08 |
| 2020 | Vote results | 2020-06-03 |
| 2020 | Proxy statement | 2020-04-28 |
| 2019 | Vote results | 2019-06-05 |
| 2019 | Proxy statement | 2019-04-26 |
| 2018 | Vote results | 2018-05-18 |
| 2018 | Proxy statement | 2018-04-17 |
Do you represent Vertex Pharmaceuticals? Claim this profile to respond to the campaigns listed here.